|
May 17-18
Big Data and the Evolution of Precision (Personalized) Medicine
George Poste, Ph.D., Chief Scientist, Complex Adaptive Systems, Professor, Health Innovation, Arizona State University
Next Steps in Cancer Immunotherapy
Eric H. Rubin, M.D., Vice President and Therapeutic Area Head, Oncology Early Development, Merck Research Laboratories
Use of Epigenetic Markers as Markers for Response in Clinical Trials
Jeffrey Waring, Ph.D., Director, Pharmacogenetics and Pharmacogenomics, Abbvie
Alpha E is the Target for Etrolizumab Treatment for Inflammatory Bowel Disease and May Predict Responses to Treatment
Teresa Ramirez Montagut, Ph.D., Scientist, Development Sciences, Genentech
Genomic Markers of Response to Anti-HER2 Therapies in Breast Cancer
Christos Hatzis, Ph.D., Assistant Professor, Medicine, and Director, Bioinformatics, Breast Medical Oncology, Yale Comprehensive Cancer Center, Yale University School of Medicine
Development of a Drug-Response Modeling Framework to Identify Cell Line-Derived Translational Biomarkers that Can Predict Treatment Outcome
William Trepicchio, Ph.D., Senior Director, Translational Medicine, Takeda
The Impact of Genomic Research during Drug Development
Rebecca Blanchard, Ph.D., Executive Director, Genetics and Pharmacogenomics, Head of Clinical Pharmacogenomics and Operations, Merck
Clinical Genomics of Solid and Liquid Biopsies in Patients with Solid Tumors
Marc Ladanyi, M.D., Attending Pathologist and Chief, Molecular Diagnostics Service; Member, Human Oncology and Pathogenesis Program, Memorial Sloan-Kettering Cancer Center, New York
Utility of Multi-Faceted Approaches for Biomarker Discovery
Darrell R. Borger, Ph.D., Director, Biomarker Laboratory, Co-Director, Translational Research Laboratory, Massachusetts General Hospital Cancer Center
Identification of Patient Subgroups through the Analysis of Blood RNA Profiling Data
Christopher Roberts, Ph.D., Associate Director, Computational Biology, Biogen Idec
Biomarkers for Patient Stratification and Precision Medicine: Cancer and Beyond
Jaya Goyal, Ph.D., Senior Director, Precision Medicine, Value Based Medicine, Biogen
Patient Selection Biomarkers – From the PDX Model Directly to the Clinic
Ann Kapoun, Ph.D., Vice President, Translational Medicine, OncoMed Pharmaceuticals
Biomarker Tests for Molecularly Targeted Therapies: Key to Unlocking Precision Medicine
Debra G.B. Leonard, M.D., Ph.D., Chair and Professor, Department of Pathology and Laboratory Medicine, University of Vermont College of Medicine and Medical Center
|
